Jenny F. Seligmann

University of Leeds — United Kingdom

Medicine · Health Sciences

19h-index3.0kcitations150works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(112), Radiomics and Machine Learning in Medical Imaging(52), Cancer Treatment and Pharmacology(47), Colorectal Cancer Surgical Treatments(26), Genetic factors in colorectal cancer(23)

Publications150 total

FOxTROT: Predictive effects of <i>ERBB2</i> and <i>ERBB3</i> on neoadjuvant panitumumab benefit in <i>RAS/BRAF</i> wild-type (-wt) locally advanced colon cancer (LACC).
Journal of Clinical Oncology·2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design
Future Oncology·2026Open Access
Supplementary Figure S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025Open Access
Relapse after resection of small bowel neuroendocrine tumours: frequency, time to relapse and post-relapse survival in a cohort of patients from the west yorkshire neuroendocrine tumour service. time to reconsider post-resection follow up?
Endocrine Abstracts·2025
785P Evaluating radiological response to neoadjuvant chemotherapy in locally advanced colon cancer: An exploratory post-hoc analysis of the FOxTROT Trial
Annals of Oncology·2025
742P Survival of patients with dMMR versus pMMR early stage colon cancer: A real-world matched study
Annals of Oncology·2025
724O Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2
Annals of Oncology·2025
CT staging performance in an international trial of neoadjuvant chemotherapy for locally advanced colon cancer
British Journal of Radiology·2025· 2 citedOpen Access
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
ESMO Open·2025· 3 citedOpen Access
50P First-line treatment in MSI-H/dMMR metastatic colorectal cancer across Europe, Canada and the United States: A real-world survey of patients and clinicians
Annals of Oncology·2025Open Access
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic <i>RAS/BRAF</i> wild-type colorectal cancer.
Journal of Clinical Oncology·2025· 1 cited
Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine
Clinical Cancer Research·2025· 5 citedOpen Access
3809 Cure vs. toxicity: quantifying preferences for non-surgical management of rectal cancer using a prospective discrete choice experiment study
Radiotherapy and Oncology·2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
ESMO Open·2025· 2 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Michel Seymour(21), Philip Quirke(21), Susan D. Richman(18), Nicholas P. West(13), Faye Elliott(12), Christopher J.M. Williams(12), Richard Adams(10), David J. Fisher(8), Tim Maughan(8), Gemma Hemmings(8), Julien Taı̈eb(7), Richard H. Wilson(7), Jennifer H. Barrett(6), Rachel Butler(6), Dion Morton(5), Sarah Brown(5), Gary Middleton(5), Louise Brown(5), Kai‐Keen Shiu(5), James Glasbey(4)